Page 26 - Read Online

Lo et al. J Cancer Metastasis Treat 2022;8:30 https://dx.doi.org/10.20517/2394-4722.2022.48 Page 11 of 12

PDAC. Future challenges in determining the optimal approach to treating patients with BR-PDAC or LA-
PDAC include not only overcoming the inherent difficulties in conducting complex, multidisciplinary,
multicentre randomized trials in patients with a high-morbidity and mortality disease, but also trying to
standardize disease definitions, treatment regimens, and outcome measures.

DECLARATIONS
Authors’ contributions
Drafted manuscript: Lo VCK
Provided supervision, reviewed manuscript: Goodwin RA, Vickers MM

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2022.

REFERENCES
1. Lippi G, Mattiuzzi C. The global burden of pancreatic cancer. Arch Med Sci 2020;16:820-4. DOI PubMed PMC
2. Lee S. Canadian cancer statistics 2021. Available from: https://cancer.ca/en/research/cancer-statistics/canadian-cancer-statistics [Last
accessed on 5 August 2022].
3. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin 2022;72:7-33. DOI PubMed
4. Katanoda K, Hori M, Saito E, et al. Updated trends in cancer in japan: incidence in 1985-2015 and mortality in 1958-2018-a sign of
decrease in cancer incidence. J Epidemiol 2021;31:426-50. DOI PubMed PMC
5. Ferlay J, Colombet M, Soerjomataram I, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25
major cancers in 2018. Eur J Cancer 2018;103:356-87. DOI PubMed
6. Paniccia A, Hosokawa P, Henderson W, et al. Characteristics of 10-year survivors of pancreatic ductal adenocarcinoma. JAMA Surg
2015;150:701-10. DOI PubMed
7. Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 2010;7:163-72.
DOI PubMed
8. Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med
2018;379:2395-406. DOI PubMed
9. Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in
patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet 2017;389:1011-24.
DOI PubMed
10. Tempero MA, Reni M, Riess H, et al. APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-
paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma. JCO 2019;37:4000. DOI
11. Versteijne E, Vogel JA, Besselink MG, et al. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with
resectable or borderline resectable pancreatic cancer. Br J Surg 2018;105:946-58. DOI PubMed PMC
12. Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas
and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999;230:776-82;